×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:HSKA

Heska Stock Forecast, Price & News

$97.87
+3.36 (+3.56%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$93.69
$98.47
50-Day Range
$84.23
$130.70
52-Week Range
$79.96
$275.94
Volume
54,599 shs
Average Volume
74,989 shs
Market Capitalization
$1.06 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$205.20

Heska Stock Forecast (MarketRank)

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
109.7% Upside
$205.20 Price Target
Short Interest
Healthy
4.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
286.21%
From $0.29 to $1.12 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.06 out of 5 stars

Medical Sector

412th out of 1,428 stocks

Diagnostic Substances Industry

5th out of 27 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive HSKA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heska and its competitors with MarketBeat's FREE daily newsletter.

Heska logo

About Heska (NASDAQ:HSKA)

Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; and turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force, and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was founded in 1988 and is based in Loveland, Colorado.

HSKA Stock News Headlines

Is Heska (NASDAQ:HSKA) Using Debt Sensibly?
Heska (NASDAQ:HSKA) Sets New 52-Week Low at $80.01
Brokerages Set Heska Co. (NASDAQ:HSKA) PT at $205.20
Oversold Conditions For Heska - Nasdaq
See More Headlines

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HSKA
Employees
655
Year Founded
N/A

Company Calendar

Last Earnings
5/09/2022
Today
7/02/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$205.20
High Stock Price Forecast
$280.00
Low Stock Price Forecast
$155.00
Forecasted Upside/Downside
+109.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-1.15 million
Pretax Margin
-6.10%

Debt

Sales & Book Value

Annual Sales
$253.74 million
Cash Flow
$1.08 per share
Book Value
$40.69 per share

Miscellaneous

Free Float
9,604,000
Market Cap
$1.06 billion
Optionable
Not Optionable
Beta
1.64














Heska Frequently Asked Questions

Should I buy or sell Heska stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Heska in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Heska stock.
View analyst ratings for Heska
or view top-rated stocks.

What is Heska's stock price forecast for 2022?

4 Wall Street analysts have issued twelve-month target prices for Heska's stock. Their HSKA stock forecasts range from $155.00 to $280.00. On average, they predict Heska's stock price to reach $205.20 in the next year. This suggests a possible upside of 109.7% from the stock's current price.
View analysts' price targets for Heska
or view top-rated stocks among Wall Street analysts.

How has Heska's stock performed in 2022?

Heska's stock was trading at $182.49 at the start of the year. Since then, HSKA shares have decreased by 46.4% and is now trading at $97.87.
View the best growth stocks for 2022 here
.

When is Heska's next earnings date?

Heska is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Heska
.

How were Heska's earnings last quarter?

Heska Co. (NASDAQ:HSKA) issued its quarterly earnings data on Monday, May, 9th. The medical research company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of $0.09 by $0.30. The medical research company earned $64.80 million during the quarter, compared to analyst estimates of $66.32 million. Heska had a negative trailing twelve-month return on equity of 0.95% and a negative net margin of 5.04%. The firm's revenue for the quarter was up 7.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.20 earnings per share.
View Heska's earnings history
.

What guidance has Heska issued on next quarter's earnings?

Heska updated its FY 2024 earnings guidance on Wednesday, June, 15th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $380.00 million-$400.00 million.

Who are Heska's key executives?

Heska's management team includes the following people:
  • Mr. Kevin S. Wilson, CEO, Pres & Director (Age 50, Pay $1.84M) (LinkedIn Profile)
  • Ms. Catherine I. Grassman CPA, Exec. VP & CFO (Age 46, Pay $583.3k) (LinkedIn Profile)
  • Dr. Nancy Wisnewski, Exec. VP & COO (Age 59, Pay $581.23k)
  • Mr. Christopher D. Sveen, EVP, Chief Admn. Officer, Gen. Counsel, Corp. Sec. & Pres of Diamond Animal Health (Age 39, Pay $536.41k)
  • Mr. Steven M. Eyl, Exec. VP, Chief Commercial Officer & Pres of scil animal care company (Age 56, Pay $587.63k)
  • Mr. Jon Aagaard, Director of Investor Relations
  • Mr. Anthony C. Providenti Jr., Exec. VP of Corp. Devel. (Age 55)
  • Ms. Eleanor F. Baker, Exec. VP, MD & COO of scil animal care company (Age 37)
  • Daniel J. Pollack, VP of Imaging Operations, Treasurer & Assistant Sec.
  • Laurie E. Peterson, VP of Heska Des Moines

What is Kevin S. Wilson's approval rating as Heska's CEO?

5 employees have rated Heska CEO Kevin S. Wilson on Glassdoor.com. Kevin S. Wilson has an approval rating of 57% among Heska's employees. This puts Kevin S. Wilson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Heska own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Gilead Sciences (GILD), Exxon Mobil (XOM), Netflix (NFLX), Biogen (BIIB), AbbVie (ABBV), Amgen (AMGN), Broadcom (AVGO), Alibaba Group (BABA), Exelixis (EXEL) and Merck & Co., Inc. (MRK).

What is Heska's stock symbol?

Heska trades on the NASDAQ under the ticker symbol "HSKA."

How do I buy shares of Heska?

Shares of HSKA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Heska's stock price today?

One share of HSKA stock can currently be purchased for approximately $97.87.

How much money does Heska make?

Heska (NASDAQ:HSKA) has a market capitalization of $1.06 billion and generates $253.74 million in revenue each year. The medical research company earns $-1.15 million in net income (profit) each year or ($1.27) on an earnings per share basis.

How many employees does Heska have?

Heska employs 655 workers across the globe.

How can I contact Heska?

Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The official website for Heska is www.heska.com. The medical research company can be reached via phone at (970) 493-7272, via email at investorrelations@heska.com, or via fax at 970-619-3003.

This page (NASDAQ:HSKA) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.